RESUMEN
Ovarian hyperstimulation syndrome (OHSS) incidentally occurs in controlled ovarian stimulation protocols and is associated with human chorionic gonadotropin (hCG) administration. OHSS is caused by increased vascular permeability (VP) and thought to be mediated by hypersecretion of vascular endothelial growth factor (VEGF) by granulosa cells. Low molecular weight (LMW)-LH agonists have a similar mode of action but a shorter half-life compared with hCG, which could potentially lead to a clinical benefit in reducing the risk for OHSS in controlled ovarian stimulation protocols. The objective of this study is to investigate the role of an orally active LMW-LH agonist in OHSS induction compared with recombinant LH (rec-LH) and hCG. Immature rats were hyperstimulated with pregnant mare serum gonadotropin, and ovulation was induced by hCG, rec-LH or a LMW-LH agonist. The degree of VP was determined by Evans Blue in the abdominal cavity. Ovaries were weighed, and VEGF concentration in the ovary was determined. Pregnant mare serum gonadotropin stimulation followed by single-dose hCG or rec-LH resulted in clear enlargement of the ovaries and increased VP and VEGF levels. However, ovulation induction with a single dose of the LMW-LH agonist did not result in increased VP and VEGF levels, and even multiple dosing to mimic a longer exposure did not induce OHSS symptoms. In conclusion, we demonstrated that the oral LMW-LH agonist did not induce VP in rat, indicative for OHSS, possibly due to reduced VEGF production. If this is translatable to human, this could potentially represent a clinical benefit in reducing the risk for OHSS when using these compounds in controlled ovarian stimulation protocols.
Asunto(s)
Gonadotropina Coriónica/uso terapéutico , Hormona Luteinizante/uso terapéutico , Síndrome de Hiperestimulación Ovárica/prevención & control , Inducción de la Ovulación/efectos adversos , Receptores de HL/agonistas , Animales , Permeabilidad Capilar/efectos de los fármacos , Gonadotropina Coriónica/farmacología , Femenino , Hormona Luteinizante/farmacología , Síndrome de Hiperestimulación Ovárica/tratamiento farmacológico , Síndrome de Hiperestimulación Ovárica/etiología , Síndrome de Hiperestimulación Ovárica/metabolismo , Ovario/irrigación sanguínea , Ovario/metabolismo , Ratas , Ratas Endogámicas Lew , Receptores de HL/metabolismoRESUMEN
BACKGROUND: In assisted reproductive technology, human chorionic gonadotrophin (hCG) is administered subcutaneously for the induction of oocyte maturation and ovulation. Our efforts to develop orally bioavailable luteinizing hormone (LH) receptor agonists have led to the discovery of Org 43553, a low molecular weight (LMW) LH receptor (LH-R) agonist. METHODS: Org 43553 was tested in vitro and in vivo in pre-clinical pharmacological models to demonstrate efficacy and oral availability. RESULTS: Org 43553 is a potent stimulator of the human LH-R in vitro (EC(50) 3.7 nM). In primary mouse Leydig cells, Org 43553 stimulated testosterone production. Pharmacokinetic analyses showed high oral bioavailability in rats (79%) and dogs (44%) with a shorter half-life compared with hCG (3.4 versus 5.6 h in the rat). Ovulation induction by Org 43553 was demonstrated in immature mice as well as in cyclic rats after single-dose oral administration (50 mg/kg). The ovulated oocytes were of good quality as demonstrated by successful fertilization and implantation of normal embryos. In male rats, testosterone production was substantially induced after oral administration. CONCLUSIONS: Org 43553 is the first LMW LH-R mimetic with demonstrated in vivo efficacy upon oral administration and could therefore replace subcutaneously administered hCG. The elimination half-life of Org 43553 is substantially shorter than hCG, which could potentially represent a clinical benefit in reducing the risk of ovarian hyperstimulation syndrome (OHSS).
Asunto(s)
Inducción de la Ovulación , Ovulación/efectos de los fármacos , Pirimidinas/farmacología , Receptores de HL/metabolismo , Tiofenos/farmacología , Administración Oral , Animales , Células CACO-2 , Gonadotropina Coriónica/metabolismo , Perros , Femenino , Humanos , Células Intersticiales del Testículo/metabolismo , Masculino , Ratones , Peso Molecular , Síndrome de Hiperestimulación Ovárica , Pirimidinas/administración & dosificación , Ratas , Ratas Wistar , Tiofenos/administración & dosificaciónAsunto(s)
Inducción de la Ovulación/métodos , Piridinas/síntesis química , Piridinas/farmacología , Pirimidinas/síntesis química , Pirimidinas/farmacología , Receptores de HL/agonistas , Tiofenos/síntesis química , Tiofenos/farmacología , Administración Oral , Animales , Células CHO/metabolismo , Cricetinae , Estradiol/síntesis química , Femenino , Humanos , Células Intersticiales del Testículo/química , Células Intersticiales del Testículo/efectos de los fármacos , Masculino , Ratones , Peso Molecular , Óvulo/efectos de los fármacos , Piridinas/química , Pirimidinas/química , Receptores de HFE/efectos de los fármacos , Receptores de HL/metabolismo , Receptores de HL/uso terapéutico , Testosterona/biosíntesis , Tiofenos/químicaRESUMEN
Org 31710 and Org 33628 are two highly selective progesterone receptor modulators (PRMs) with respect to their anti-progestational and anti-glucocorticoid activity. The compounds have been studied both in vitro and in vivo. Org 33628 has approximately four times stronger anti-progestational activity in vitro than does Org 31710, and in rats it is about 15 times more potent in the pregnancy interruption test. Two main indications for the use of PRMs are breast cancer and fertility regulation. The effects of both Org 31710 and Org 33628 were tested in relevant models for these indications. The effects of the two compounds on breast tumor development were assessed and in rats using the DMBA model. Their potency in menses induction was tested in monkeys on a 4-day regimen in the luteal phase, and after a single dose at day 21 of the normal cycle, and under a continuous progestin treatment using desogestrel. The compounds were also tested alone in a continuous low-dose regimen. The effects on follicular development and ovulation were determined by measuring estradiol and progesterone levels. Cycle control was monitored by daily vaginal swabs. In the DMBA model, Org 31710 at oral doses of 0.8, 2.0, and 5.0 mg/kg showed a clear dose-related reduction in tumor load. With the two highest doses, an even lower tumor load was seen after a 3-week treatment period compared to the tumor load at the start of treatment. Org 33628 showed a similar efficacy as Org 31710 at a dose of 2.0 mg/kg. RU 486 after oral treatment was two times less potent in this model than Org 31710 and Org 33628. The efficacy of menses induction using the 4-day regimen is dependent on the time of administration relative to the progesterone peak in the luteal phase. The highest efficacy is achieved in the descending part of the peak, at which a 100% success rate is found with a dose of 1 mg/kg of either Org 31710 or Org 33628. In Cynomolgus monkeys, at a single dose of 15 mg/kg of Org 31710 or Org 33628 in the luteal phase, menses induction was achieved only in 60% of the treatment cycles. Surprisingly menses induction can be achieved with a single dose that is about a ten-times lower when the monkeys are treated continuously with desogestrel. Cycle control is better at low than at high doses of antiprogestin in combination with daily dosing of 4 microg/kg desogestrel. Despite the difference in receptor affinity, no difference between Org 31710 and Org 33628 was found in menses induction. In the continuous low-dose (1 mg/kg) regimen with the PRMs, follicular development occurs normally while ovulation is inhibited. Ovulation is resumed shortly after stopping treatment, and a normal menses occurs after the first progesterone peak. Both compounds may be interesting options for the prevention and treatment of breast cancer and for fertility control.
Asunto(s)
Endometrio/efectos de los fármacos , Estrenos/farmacología , Furanos/farmacología , Animales , Neoplasias de la Mama/tratamiento farmacológico , División Celular/efectos de los fármacos , Tamaño de la Célula/efectos de los fármacos , Anticonceptivos Femeninos/farmacología , Anticonceptivos Femeninos/uso terapéutico , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Endometrio/citología , Estrenos/uso terapéutico , Femenino , Furanos/uso terapéutico , Antagonistas de Hormonas/farmacología , Antagonistas de Hormonas/uso terapéutico , Humanos , Macaca fascicularis , Menstruación/efectos de los fármacos , Inductores de la Menstruación/farmacología , Neoplasias Experimentales/tratamiento farmacológico , Ratas , Receptores de Progesterona/agonistas , Receptores de Progesterona/antagonistas & inhibidores , Relación Estructura-Actividad , Células Tumorales CultivadasRESUMEN
To investigate ovulation, an in vitro model with cultured mouse follicles was developed and compared with an in vivo ovulation model. In this model, secondary follicles were grown in vitro with immature mouse serum (5%) and recombinant human FSH. Addition of ascorbic acid and selenium to the medium increased follicular survival (from 29% to 86%) and resulted in the development of healthy preovulatory follicles (> 400 microm) producing estradiol. Depending on the starting size of the follicles, the preovulatory stage was reached after 4-6 days. The ovulatory response to hCG was maximal in follicles exceeding a diameter of 400 microm. The in vitro-ovulated oocytes could be fertilized and were able to develop to the blastocyst stage. Ovulation induced by hCG was dose dependent, reaching a maximum of 80% at 1 IU/ml. Concomitantly, progesterone production increased from 3.6 +/- 0.5 to 29 +/- 2 ng/ml. Both in vivo and in vitro, hCG induced expression of the progesterone receptor and the prostaglandin endoperoxide synthase-2 (PGS-2) gene within 3 h. Ovulation could be completely blocked with the anti-progestogen Org-31710 and partially (50%) with the PGS inhibitor indomethacin in vitro and in vivo. Org-31710 and indomethacin did not affect progesterone production. In summary, a physiologically relevant in vitro ovulation model of cultured mouse follicles that can be used to study the process of follicular rupture has been developed.
Asunto(s)
Folículo Ovárico/crecimiento & desarrollo , Ovulación , Animales , Ácido Ascórbico/farmacología , Gonadotropina Coriónica/farmacología , Técnicas de Cultivo , Ciclooxigenasa 2 , Estrenos/farmacología , Femenino , Furanos/farmacología , Antagonistas de Hormonas/farmacología , Humanos , Indometacina/farmacología , Ratones , Folículo Ovárico/efectos de los fármacos , Inducción de la Ovulación , Prostaglandina-Endoperóxido Sintasas/metabolismo , Selenio/farmacologíaRESUMEN
During each reproductive cycle, a preovulatory surge of gonadotropins induces meiotic maturation of the oocyte in the preovulatory follicle followed by ovulation. Although gonadotropins stimulate cAMP production in somatic cells of the follicle, a decrease in intra-oocyte cAMP levels is required for resumption of meiosis in oocytes. Based on the observed compartmentalization of the cAMP-degrading enzyme, phosphodiesterase, in follicular somatic and germ cells, inhibitors of phosphodiesterase 3 were used to block meiosis in ovulating oocytes in rodents. By this strategy, we demonstrated that fertilization and pregnancy could be prevented without disturbing follicle rupture and normal estrous cyclicity. In contrast to conventional contraceptive pills that disrupt ovarian steroidogenesis and reproductive cycles, the present strategy achieves effective contraception by selective blockage of oocyte maturation and development without alterations in ovulation and reproductive cyclicity.
Asunto(s)
3',5'-AMP Cíclico Fosfodiesterasas/antagonistas & inhibidores , Anticonceptivos Femeninos/farmacología , AMP Cíclico/fisiología , Estro/efectos de los fármacos , Meiosis/efectos de los fármacos , Oogénesis/efectos de los fármacos , Ovulación/efectos de los fármacos , Inhibidores de Fosfodiesterasa/farmacología , Sistemas de Mensajero Secundario/fisiología , 1-Metil-3-Isobutilxantina/farmacología , Animales , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3 , Femenino , Fertilización/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Hipoxantina/farmacología , Isoenzimas/antagonistas & inhibidores , Menotropinas/farmacología , Ratones , Ratones Endogámicos C57BL , Milrinona , Folículo Ovárico/efectos de los fármacos , Folículo Ovárico/fisiología , Inducción de la Ovulación , Embarazo , Purinonas/farmacología , Piridazinas/farmacología , Piridonas/farmacología , Pirrolidinonas/farmacología , Quinolonas/farmacología , Ratas , Ratas Sprague-Dawley , Rolipram , Especificidad por Sustrato , Tiofenos/farmacologíaRESUMEN
The kinetics and hypocalcemic potency of stanniocalcin (STC) were examined in freshwater and seawater eels. The secretion rate and the metabolic clearance rate of STC were calculated from the STC disappearance curve after intra-arterial injection of trout STC. Basal plasma STC concentrations in freshwater and seawater eels did not differ but the STC secretion rate and metabolic clearance rate in seawater eel were 70-75% higher than in FW eel. The increased STC distribution space in seawater eels suggests that the STC receptor density was increased. STC had a higher hypocalcemic potency in seawater than in freshwater eels. These observations support the hypothesis that seawater fish require more hormonal control over transcellular influx of calcium than freshwater fish.
RESUMEN
The release in vivo and in vitro of stanniocalcin (STC) from the corpuscles of Stannius (CS) of the rainbow trout and the European eel was studied. Intraperitoneal injection of CaCl2 (2.45 mmol.kg-1 fish) leads to an elevation of both ionic and total calcium in the plasma and results in the release of STC from the CS into the blood. Release of STC in vitro is not affected at "physiological" (1.0-1.5 mM) or lower Ca2+ levels in the incubation medium. High levels of Ca2+ (2.5 mM and higher), however, stimulate the release of STC, in particular that of stored STC. We hypothesize that variations in extracellular Ca2+ in the normocalcaemic range do not directly regulate STC release.
Asunto(s)
Calcio/farmacología , Expresión Génica/efectos de los fármacos , Glicoproteínas/metabolismo , Hormonas , Animales , Calcimicina/farmacología , Calcio/farmacocinética , Carbacol/farmacología , Relación Dosis-Respuesta a Droga , Anguilas , Ensayo de Inmunoadsorción Enzimática , Hipercalcemia/inducido químicamente , Hipercalcemia/metabolismo , Técnicas In Vitro , Inyecciones Intraperitoneales , Microscopía Electrónica , TruchaRESUMEN
In fresh-water rainbow trout, Oncorhynchus mykiss (formerly called Salmo gairdneri), experimentally induced mild hypercalcemia results in release of immunoreactive stanniocalcin from the corpuscles of Stannius (CS) and stimulated synthetic and releasing activities of the glands as measured in vitro. Pulse-chase experiments showed that stanniocalcin (STC) is a 56-kDa glycoprotein, processed from a 64-kDa precursor, prostanniocalcin (PSTC). PSTC and STC are homodimeric molecules that are readily split into monomers in the presence of reducing agents such as 2-mercaptoethanol. The monomeric form of PSTC and STC contains an approximately 5- to 6-kDa glycomoiety. Neither this sugar residue nor the NH2-terminal amino acid sequences of PSTC or STC proved to contain antigenic sites for the antiserum used in this study. Two-dimensional gel electrophoresis indicated the presence of several isoforms of PSTC and STC molecules that may reflect different stages of maturation of the (pro)hormone.
Asunto(s)
Glándulas Endocrinas/metabolismo , Glicoproteínas/biosíntesis , Hormonas , Salmonidae/metabolismo , Trucha/metabolismo , Animales , Western Blotting , Calcio/sangre , Concanavalina A , Cisteína/farmacología , Electroforesis/métodos , Ensayo de Inmunoadsorción Enzimática , Femenino , Glucosamina/farmacología , Técnicas In Vitro , Masculino , Pruebas de Precipitina , Trucha/sangreRESUMEN
Removal of the corpuscles of Stannius (STX) in the freshwater European eel causes a marked increase in the concentrations of blood ionic calcium and protein-bound calcium. The hypercalcaemia peaks 20 days after STX and lasts at least another 20 days. In stanniectomized eels hypocalcin decreased both blood ionic and total calcium concentrations. The reduction of plasma total calcium concentration by hypocalcin is attributed to a reduction in blood ionic calcium concentration. We conclude that hypocalcin regulates blood ionic calcium levels in fish.
Asunto(s)
Anguilla/sangre , Calcio/sangre , Glicoproteínas/farmacología , Hormonas , AnimalesRESUMEN
We have isolated and purified a glycoprotein from the corpuscles of Stannius (CS) of trout, which we consider hypocalcin (also called teleocalcin), the major hypocalcemic hormone of fish. This product is present in relatively large amounts in the CS of several species (i.e., European eel, tilapia, goldfish, and carp). Hypocalcin is typically released from the CS in response to an experimentally induced increase of the blood calcium concentration. Ultrastructural observations show that after this treatment the type 1 cells, reportedly the hypocalcin-producing cell type of the CS, are almost completely degranulated. The isolated glycoprotein has an apparent molecular weight of 54 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This molecule appears susceptible to breakdown and is recovered upon concanavalin-A affinity chromatography as a 41 kDa product. Reducing agents such as mercaptoethanol or dithiothreitol employed, e.g., during standard electrophoretic techniques or during amino acid sequence analysis, allow only the recovery of 28 or 18 kDa products. Evidence is given that the 54 and 41 kDa products are dimer molecules, with the 28 and 18 kDa products as their respective monomeric constituents. The sequence of the first 33 N-terminal amino acids of these products and the composition of the sugar component are presented.